Clemastine Fumarate as Remyelinating Treatment in ... | 農藥百科
2022年4月21日—LastUpdatePosted:April21,2022...MultipleSclerosisInternuclearOphthalmoplegia,Drug:ClemastineFumarateDrug:Placebo,Phase3 ...
Rationale: Clemastine fumarate has been identified as potential remyelinating therapy for multiple sclerosis (MS). The (long-term) effects of clemastine need to be confirmed in clinical models for MS. Internuclear ophthalmoparesis (INO) may be used as a clinical model for investigating remyelinating therapies by measuring horizontal eye movements with infrared oculography. Furthermore, infrared oculography combined with a single dose of fampridine may be used to identify individuals with MS that are most likely to benefit from remyelinating therapy.
Objective: To assess the (long-term) efficacy of clemastine fumarate in improving dysconjugacy of eye movements in patients with internuclear ophthalmoparesis and multiple sclerosis. Secondly, to assess whether a response to a single dose of fampridine can predict the effects of clemastine treatment.
Study design: A single-centre double-blind ra...